Liver enzymes elevation after HAART in HIV-HCV co-infection

Luis Servin-Abad, E. Molina, Gio Baracco, Leopoldo Arosemena, A. Regev, Lennox J Jeffers, Eugene R Schiff

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) co-infection is common among human immunodeficiency virus (HIV) patients. The incidence and risk factors associated with hepatotoxicity in this population after high active antiretroviral therapy (HAART) is initiated are still not well-understood. We argued to evaluate the incidence and risk factors associated with liver enzyme elevation (LEE) and their clinical significance. A retrospective chart review of patients who started HAART and had follow up at our centre for at least 1 year was undertaken. The frequency and severity of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation after treatment initiation were investigated and searched for clinical manifestations. Between January 1996 and March 2002, 85 HIV-HCV co-infected patients began HAART and continued follow up for at least 1 year. The incidence of severe toxicity [grades 3 + 4 LEE: > 5 and > 10 times the upper limit of normal (ULN) of ALT or AST] was calculated at 4% per person-years. There were no clinical manifestations of liver toxicity, and patients continued their treatment with a trend towards a decrease of their enzymes. No statistical differences in opportunistic infections or mortality were evident. The variables associated with severe hepatotoxicity were a higher baseline AST, higher international normalized ratio (INR) and lower albumin. A baseline AST < 2.1 ULN had a negative predictive value of 92% of leading to severe hepatotoxicity. In HIV-HCV co-infected patients therefore, the group at a higher risk of developing higher transaminase elevations is the one with a higher baseline AST, higher INR and lower albumin.

Original languageEnglish
Pages (from-to)429-434
Number of pages6
JournalJournal of Viral Hepatitis
Volume12
Issue number4
DOIs
StatePublished - Jul 1 2005

Fingerprint

Virus Diseases
Aspartate Aminotransferases
Coinfection
Hepacivirus
HIV
Liver
Enzymes
International Normalized Ratio
Alanine Transaminase
Albumins
Incidence
Therapeutics
Opportunistic Infections
Transaminases
Mortality
Population

Keywords

  • Antiretrovirals
  • Hepatitis C
  • Hepatotoxicity
  • High active antiretroviral therapy
  • Human immunodeficiency virus
  • Liver enzymes

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Liver enzymes elevation after HAART in HIV-HCV co-infection. / Servin-Abad, Luis; Molina, E.; Baracco, Gio; Arosemena, Leopoldo; Regev, A.; Jeffers, Lennox J; Schiff, Eugene R.

In: Journal of Viral Hepatitis, Vol. 12, No. 4, 01.07.2005, p. 429-434.

Research output: Contribution to journalArticle

Servin-Abad, Luis ; Molina, E. ; Baracco, Gio ; Arosemena, Leopoldo ; Regev, A. ; Jeffers, Lennox J ; Schiff, Eugene R. / Liver enzymes elevation after HAART in HIV-HCV co-infection. In: Journal of Viral Hepatitis. 2005 ; Vol. 12, No. 4. pp. 429-434.
@article{46a2fba0d14a4aa3acce639e779d1ffc,
title = "Liver enzymes elevation after HAART in HIV-HCV co-infection",
abstract = "Hepatitis C virus (HCV) co-infection is common among human immunodeficiency virus (HIV) patients. The incidence and risk factors associated with hepatotoxicity in this population after high active antiretroviral therapy (HAART) is initiated are still not well-understood. We argued to evaluate the incidence and risk factors associated with liver enzyme elevation (LEE) and their clinical significance. A retrospective chart review of patients who started HAART and had follow up at our centre for at least 1 year was undertaken. The frequency and severity of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation after treatment initiation were investigated and searched for clinical manifestations. Between January 1996 and March 2002, 85 HIV-HCV co-infected patients began HAART and continued follow up for at least 1 year. The incidence of severe toxicity [grades 3 + 4 LEE: > 5 and > 10 times the upper limit of normal (ULN) of ALT or AST] was calculated at 4{\%} per person-years. There were no clinical manifestations of liver toxicity, and patients continued their treatment with a trend towards a decrease of their enzymes. No statistical differences in opportunistic infections or mortality were evident. The variables associated with severe hepatotoxicity were a higher baseline AST, higher international normalized ratio (INR) and lower albumin. A baseline AST < 2.1 ULN had a negative predictive value of 92{\%} of leading to severe hepatotoxicity. In HIV-HCV co-infected patients therefore, the group at a higher risk of developing higher transaminase elevations is the one with a higher baseline AST, higher INR and lower albumin.",
keywords = "Antiretrovirals, Hepatitis C, Hepatotoxicity, High active antiretroviral therapy, Human immunodeficiency virus, Liver enzymes",
author = "Luis Servin-Abad and E. Molina and Gio Baracco and Leopoldo Arosemena and A. Regev and Jeffers, {Lennox J} and Schiff, {Eugene R}",
year = "2005",
month = "7",
day = "1",
doi = "10.1111/j.1365-2893.2005.00617.x",
language = "English",
volume = "12",
pages = "429--434",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Liver enzymes elevation after HAART in HIV-HCV co-infection

AU - Servin-Abad, Luis

AU - Molina, E.

AU - Baracco, Gio

AU - Arosemena, Leopoldo

AU - Regev, A.

AU - Jeffers, Lennox J

AU - Schiff, Eugene R

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Hepatitis C virus (HCV) co-infection is common among human immunodeficiency virus (HIV) patients. The incidence and risk factors associated with hepatotoxicity in this population after high active antiretroviral therapy (HAART) is initiated are still not well-understood. We argued to evaluate the incidence and risk factors associated with liver enzyme elevation (LEE) and their clinical significance. A retrospective chart review of patients who started HAART and had follow up at our centre for at least 1 year was undertaken. The frequency and severity of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation after treatment initiation were investigated and searched for clinical manifestations. Between January 1996 and March 2002, 85 HIV-HCV co-infected patients began HAART and continued follow up for at least 1 year. The incidence of severe toxicity [grades 3 + 4 LEE: > 5 and > 10 times the upper limit of normal (ULN) of ALT or AST] was calculated at 4% per person-years. There were no clinical manifestations of liver toxicity, and patients continued their treatment with a trend towards a decrease of their enzymes. No statistical differences in opportunistic infections or mortality were evident. The variables associated with severe hepatotoxicity were a higher baseline AST, higher international normalized ratio (INR) and lower albumin. A baseline AST < 2.1 ULN had a negative predictive value of 92% of leading to severe hepatotoxicity. In HIV-HCV co-infected patients therefore, the group at a higher risk of developing higher transaminase elevations is the one with a higher baseline AST, higher INR and lower albumin.

AB - Hepatitis C virus (HCV) co-infection is common among human immunodeficiency virus (HIV) patients. The incidence and risk factors associated with hepatotoxicity in this population after high active antiretroviral therapy (HAART) is initiated are still not well-understood. We argued to evaluate the incidence and risk factors associated with liver enzyme elevation (LEE) and their clinical significance. A retrospective chart review of patients who started HAART and had follow up at our centre for at least 1 year was undertaken. The frequency and severity of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation after treatment initiation were investigated and searched for clinical manifestations. Between January 1996 and March 2002, 85 HIV-HCV co-infected patients began HAART and continued follow up for at least 1 year. The incidence of severe toxicity [grades 3 + 4 LEE: > 5 and > 10 times the upper limit of normal (ULN) of ALT or AST] was calculated at 4% per person-years. There were no clinical manifestations of liver toxicity, and patients continued their treatment with a trend towards a decrease of their enzymes. No statistical differences in opportunistic infections or mortality were evident. The variables associated with severe hepatotoxicity were a higher baseline AST, higher international normalized ratio (INR) and lower albumin. A baseline AST < 2.1 ULN had a negative predictive value of 92% of leading to severe hepatotoxicity. In HIV-HCV co-infected patients therefore, the group at a higher risk of developing higher transaminase elevations is the one with a higher baseline AST, higher INR and lower albumin.

KW - Antiretrovirals

KW - Hepatitis C

KW - Hepatotoxicity

KW - High active antiretroviral therapy

KW - Human immunodeficiency virus

KW - Liver enzymes

UR - http://www.scopus.com/inward/record.url?scp=21844468526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844468526&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2005.00617.x

DO - 10.1111/j.1365-2893.2005.00617.x

M3 - Article

VL - 12

SP - 429

EP - 434

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 4

ER -